

4- (withdrawn) Method according to claim 1, wherein the NO releasing agent in said ophthalmic medicament is O-nitrosylated compounds also known as O-nitroso compounds or in some cases organic nitrites.

5- (withdrawn) Method according to claim 1, wherein the NO releasing agent in said ophthalmic medicament is S-nitrosylated compounds also known as S-nitroso compounds or S-nitrosothiols compounds such as glutathione.

6-(withdrawn) Method according to claim 1, wherein the NO releasing agent in said ophthalmic medicament is S-nitrosylated derivatives of captopril.

7- (withdrawn) Method according to claim 1, wherein the NO releasing agent in said ophthalmic medicament is S-nitrosylated-proteins/peptides.

8- (withdrawn) Method according to claim 1, wherein the NO releasing agent in said ophthalmic medicament is S-nitrosylated oligosaccharides and polysaccharides.

9- (withdrawn) Method according to claim 1, wherein the NO releasing agent in said ophthalmic medicament is Nonoates compounds such as piperazines 2 and diazeniumdiolates.

10- (amended) Method according to claims 1and 2, wherein the NO releasing agent in said ophthalmic medicament is sodium nitroprusside.

11- (withdrawn) Method according to claim 1, wherein the NO releasing agent in said ophthalmic medicament is Sydnonimines.

12- (withdrawn) Method according to claim 1, wherein the NO releasing agent in said ophthalmic medicament is L-arginine (which does not release NO directly, but rather is an enzyme substrate which leads to the formation of nitric oxide in vivo).

13- (withdrawn) Method according to claim 1, wherein the NO releasing agent in said ophthalmic medicament is 1,3-(nitrooxymethyl)phenyl 2-hydroxybenzoate isosorbide dinitrate.

14- (withdrawn) Method according to claim 1, wherein the NO releasing agent in said ophthalmic medicament is pyrimidine (also known as Minoxidil or Rogaine<sup>TM</sup>).

15- (amended) Method according to claims 1 and 2, wherein the cGMP specific PDE-5 inhibitor in said ophthalmic solution is (sildenafil) also known as 1-[[3-(6,7-dihydro-1 methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-- yl)-4 ethoxyphenyl]sulphonyl]-4-methylpiperazine.

16- (withdrawn) Method according to claim 1, wherein the cGMP specific PDE-5 inhibitor in said ophthalmic solution is sildenafil citrate, (Viagra<sup>TM</sup>) also known as 1-[[3(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyri- midin-5-yl)4 ethoxyphenyl]sulphonyl]-4-methylpiperazine citrate.

17- (withdrawn) Method according to claim 1, wherein the cGMP specific PDE-5 inhibitor in said ophthalmic solution is 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphon- yl)-2n-propoxyphenyl]-2 -(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3- d]pyrimidin-7-one.

18- (withdrawn) Method according to claim 1, wherein the cGMP specific PDE-5 inhibitor in said ophthalmic solution is 1-{6-ethoxy-5-[3-ethyl-6,7-dihydro-2-(2-me- thoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5yl]-3 pyridylsulphonyl}-4-ethylpiperazine.